Back to search

Peptide record

TPDB09849

Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09849
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AFP-GFuse Antifungipept CAFPdb APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
RWCVYAYVRVRGVLVRYRRCW
Physicochemical Analysis
C127H195N41O25S2
NDEQHIKMFPST
R
2760.33
11.11
6
0
12
+6
-2.51
-0.071
92.38
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
15595
564.97
5
Residue Composition
number
1
A
6
R
0
N
0
D
2
C
0
E
0
Q
1
G
0
H
0
I
1
L
0
K
0
M
0
F
0
P
0
S
0
T
2
W
3
Y
5
V
Amino Acid Distribution
A: 1 R: 6 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 1 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 2 Y: 3 V: 5
Chemical Descriptors
21
C127H195N41O25S2
2760.33
11.11
+6
-2.51
-0.071
Evidence Records 21 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.6 µg/mL

Target

L. monocytogenes EGD

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against L. monocytogenes EGD (MIC 0.6 ug/ml), Gram-negative E. coli ML-35p (MIC 4 ug/ml) and fungi C. albicans 820 (MIC 4.5 ug/ml). Al
Evidence 2 Activity

Activity

MIC
Antibacterial
4 µg/mL

Target

Escherichia coli ML-35p

Source & Reference

dbAMP DRAMP

Other

active against L. monocytogenes EGD (MIC 0.6 ug/ml), Gram-negative E. coli ML-35p (MIC 4 ug/ml) and fungi C. albicans 820 (MIC 4.5 ug/ml). Also active against M. abscessus (MIC90 19 uM)
Evidence 3 Activity

Activity

MIC
Antibacterial
4.5 µg/mL

Target

Candida albicans 820

Source & Reference

dbAMP DRAMP

Other

. monocytogenes EGD (MIC 0.6 ug/ml), Gram-negative E. coli ML-35p (MIC 4 ug/ml) and fungi C. albicans 820 (MIC 4.5 ug/ml). Also active against M. abscessus (MIC90 19 uM).
Evidence 4 Activity

Activity

MIC
Antifungal
0.6 µg/mL

Target

L. monocytogenes EGD

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
active against L. monocytogenes EGD (MIC 0.6 ug/ml), Gram-negative E. coli ML-35p (MIC 4 ug/ml) and fungi C. albicans 820 (MIC 4.5 ug/ml). Al
Evidence 5 Activity

Activity

MIC
Antifungal
4 µg/mL

Target

Escherichia coli ML-35p

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

active against L. monocytogenes EGD (MIC 0.6 ug/ml), Gram-negative E. coli ML-35p (MIC 4 ug/ml) and fungi C. albicans 820 (MIC 4.5 ug/ml). Also active against M. abscessus (MIC90 19 uM)
Evidence 6 Activity

Activity

MIC
Antifungal
4.5 µg/mL

Target

Candida albicans 820

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

. monocytogenes EGD (MIC 0.6 ug/ml), Gram-negative E. coli ML-35p (MIC 4 ug/ml) and fungi C. albicans 820 (MIC 4.5 ug/ml). Also active against M. abscessus (MIC90 19 uM).
Evidence 7 Activity

Activity

MIC
Antiparasitic
0.6 µg/mL

Target

L. monocytogenes EGD

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
active against L. monocytogenes EGD (MIC 0.6 ug/ml), Gram-negative E. coli ML-35p (MIC 4 ug/ml) and fungi C. albicans 820 (MIC 4.5 ug/ml). Al
Evidence 8 Activity

Activity

MIC
Antiparasitic
4 µg/mL

Target

Escherichia coli ML-35p

Source & Reference

DRAMP

Other

active against L. monocytogenes EGD (MIC 0.6 ug/ml), Gram-negative E. coli ML-35p (MIC 4 ug/ml) and fungi C. albicans 820 (MIC 4.5 ug/ml). Also active against M. abscessus (MIC90 19 uM)
Evidence 9 Activity

Activity

MIC
Antiparasitic
4.5 µg/mL

Target

Candida albicans 820

Source & Reference

DRAMP

Other

. monocytogenes EGD (MIC 0.6 ug/ml), Gram-negative E. coli ML-35p (MIC 4 ug/ml) and fungi C. albicans 820 (MIC 4.5 ug/ml). Also active against M. abscessus (MIC90 19 uM).
Evidence 10 Activity

Activity

0% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
0% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The characteristic region of arenicin-1 involved with a bacterial membrane targeting mechanism. | Biochem Biophys Res Commun | 2011
Evidence 11 Activity

Activity

12% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
12% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The characteristic region of arenicin-1 involved with a bacterial membrane targeting mechanism. | Biochem Biophys Res Commun | 2011
Evidence 12 Activity

Activity

35% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
35% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The characteristic region of arenicin-1 involved with a bacterial membrane targeting mechanism. | Biochem Biophys Res Commun | 2011
Evidence 13 Activity

Activity

51% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
51% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The characteristic region of arenicin-1 involved with a bacterial membrane targeting mechanism. | Biochem Biophys Res Commun | 2011
Evidence 14 Activity

Activity

10% Hemolysis
Toxicity
4.1 µM
Hemolytic Cytotoxic
10% Hemolysis | 4.1 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of antimicrobial peptide arenicin analogs with improved therapeutic indices. | J Pept Sci | 2015
Evidence 15 Activity

Activity

15% Hemolysis
Toxicity
10.3 µM
Hemolytic Cytotoxic
15% Hemolysis | 10.3 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigning Arenicin-1, an Antimicrobial Peptide from the Marine Polychaeta Arenicola marina, by Strand Rearrangement or Branching, Substitution of Specific Residues, and Backbone Linearization or Cyclization. | Mar Drugs | 2019
Evidence 16 Activity

Activity

50% Hemolysis
Toxicity
66.3 µM
Hemolytic Cytotoxic
50% Hemolysis | 66.3 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigning Arenicin-1, an Antimicrobial Peptide from the Marine Polychaeta Arenicola marina, by Strand Rearrangement or Branching, Substitution of Specific Residues, and Backbone Linearization or Cyclization. | Mar Drugs | 2019
Evidence 17 Activity

Activity

50% Cytotoxicity
Toxicity
>100 µM
Cytotoxic
50% Cytotoxicity | >100 | µM | target cell: Human bronchial epithelial cells BEAS-2B

Target

Human bronchial epithelial cells BEAS-2B

Source & Reference

NA
DBAASP
Promising antibacterial efficacy of arenicin peptides against the emerging opportunistic pathogen Mycobacterium abscessus | J Biomed Sci | 2024
Evidence 18 Activity

Activity

15% Hemolysis
Toxicity
14 µM
Hemolytic Cytotoxic
15% Hemolysis | 14 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigning Arenicin-1, an Antimicrobial Peptide from the Marine Polychaeta Arenicola marina, by Strand Rearrangement or Branching, Substitution of Specific Residues, and Backbone Linearization or Cyclization. | Mar Drugs | 2019
Evidence 19 Activity

Activity

50% Hemolysis
Toxicity
65.5 µM
Hemolytic Cytotoxic
50% Hemolysis | 65.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigning Arenicin-1, an Antimicrobial Peptide from the Marine Polychaeta Arenicola marina, by Strand Rearrangement or Branching, Substitution of Specific Residues, and Backbone Linearization or Cyclization. | Mar Drugs | 2019
Evidence 20 Activity

Activity

% Hemolysis
Toxicity
50 %
Cytotoxic
Cytotoxicity: [Ref.27940358] Cytotoxicity: human embryonic fibroblasts (HEF) and human red blood cells (hRBC)(IC50 for arenicin-1 in the presence or absence of 10% FBS were of 35 and 8 µM,HC50 indicating 50% hemolysis after 24 h incubation, equaled to 16µM).

Source & Reference

NA
DRAMP
FEBS Lett. 2004 Nov 5 577(1-2):209-214.##Biochem J. 2008 Feb 15 410(1):113-122.
Evidence 21 Hemolysis

Source & Reference

APD_complete HemoPI PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.